To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
All the news of the Institute of life sciences Frédéric Joliot
To determine the pharmacological profiles of the peptides studied in the laboratory and in particular those that are highly reticulated, we have optimized their solid-phase peptide synthesis (SPPS) and refolding processes. SPPS allows us to make engineering of the desired molecules, including specific fluorescent or radioactive labeling, sequence modifications (variants for structure-activity relationships, deimmunization attempt or pharmacodynamic optimization), or multiple functionalization. Introduction of non-natural amino acids (biotinylation, azido moiety able to react with an alkyne for peptidomimetic compounds…), post-translational modifications (C-terminal amidation, hydroxy-proline, tyrosine sulfate…), endosomal escape domains insertion (to make a peptide able to cross the membrane barrier) are the main modifications we introduce in our molecules. These changes influence the stability or functional properties of the toxins studied and reinforce their exploitation as imaging or therapeutic agents (Salinas et al., 2021) (Droctove et al., 2020) (Mourier et al., 2016) (Fruchart-Gaillard et al., 2012).
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.